|
|
|
| The Role of NLRC3 in the Tumor Immune Mechanism Involved in the Pathogenesis of Endometriosis |
| HAO Mengqi, JI Peiyun, GAO Xiujuan, et al |
| Affiliated Hospital of Chengde Medical University, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To explore the expression of Nucleotide-binding Oligomerization Domain (NOD)-like receptor family CARD domain-containing protein 3 (NLRC3) in ovarian ectopic endometrial tissues of stage III and IV endometriosis (EMT) patients and its relationship with clinical pathological features. Methods: Immunohistochemistry, Western Blot, and qRT-PCR were used to detect the expression of NLRC3 in 17 cases of stage III, 17 cases of stage IV ovarian ectopic endometrial tissues, and 17 cases of normal endometrial tissues. The relationship between NLRC3 and clinical pathological features of EMT patients was analyzed. Results: Compared with normal endometrial tissues, the expression level of NLRC3 was decreased in stage III and stage IV ectopic endometrial tissues (P<0.05), while there was no statistically significant difference in NLRC3 expression between stage III and stage IV endometriosis patients (P>0.05). The positive rate of NLRC3 protein expression was lower in patients with higher CA125 levels (P<0.05). There was no statistically significant difference in NLRC3 expression among EMT patients of different ages, lesion sizes, and degrees of dysmenorrhea (P>0.05). Conclusion: The pathogenesis of EMT is associated with immune imbalance in the peritoneal microenvironment, and the decreased or lost immune surveillance function of NLRC3 may be involved in the occurrence and development of EMT. The combined detection of CA125 and NLRC3 expression may play a significant role in predicting or diagnosing EMT.
|
|
|
|
|
|
[1] Kvaskoff M,Mahamat-Saleh Y,Farland LV,et al.Endometriosis and cancer:a systematic review and meta-analysis[J].Hum ReProd UPdate,2021,27(2):393-420.
[2] Shigesi N,Kvaskoff M,Kirtley S,et al.The association between endometriosis and autoimmune diseases:a systematic review and meta-analysis[J].Hum Reprod Update,2019,25(4):486-503.
[3] Johnson NP,Hummelshoj L,Adamson GD,et al.World endometriosis society consensus on the classification of endometriosis[J].Hum ReProd,2017,32(2):315-324.
[4] Madanes D,Bilotas MA,Bastón JI,et al.PI3K/AKT pathway is altered in the endometriosis Patient's endometrium and Presents differences according to severity stage[J].Gynecol Endocrinol,2020,36(5):436-440.
[5] Symons LK,Miller JE,Kay VR,et al.The immuno patho physiology of endometriosis[J].Trends Mol Med,2018,24(9):748-762.
[6] Uchimura T,Oyama Y,Deng M,et al.The innate immune sensor NLRC3 Acts as a rheostat that fine-tunes T cell res ponses in infection and autoimmunity[J].Immunity,2018,49(6):1049-1061.
[7] Fu Y,Zhan X,Wang Y,et al.NLRC3 exPression in dendritic cells attenuates CD4 T cell resPonse and autoimmunity[J].EMBO,2019,38(16):101397.
[8] Kang JH,Li MJ,Luan PP,et al.NLRC3 silencing accelerates the invasion of hePatocellular carcinoma cell via IL-6/JAK2/STAT3 Pathway activation[J].Cell Biol Int,2020,44(10):2053-2064.
[9] Karki R,Man SM,Malireddi RKS,et al.NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer[J].Nature,2016,540(7634):583-587.
[10] Suryawanshi S,Huang X,Elishaev E,et al.Complement pathway is frequently altered in endometriosis and endometriosis-associated ovarian cancer[J].Clin Cancer Res,2014,20(23):6163-6174.
[11] Greten FR,Grivennikov SI.Inflammation and cancer:triggers,mechanisms and consequences[J].Immunity,2019,51(1):27-41. |
|
|
|
2023, Vol. 29 
